Paper
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study
Published Jan 30, 2015 · R. Nishimura, Yuko Tanaka, Kazuki Koiwai
Cardiovascular Diabetology
107
Citations
2
Influential Citations
Abstract
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study Abstract Background: This study evaluated the effect of empagliflozin on postprandial glucose (PPG) and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus (T2DM).
RCTVery Rigorous JournalHighly Cited
Study Snapshot
Emagliflozin monotherapy effectively reduces postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Full text analysis coming soon...
References
—
···
—
···
—
···
—
···
—
···
—
···
—
···
—
···
Citations
—
···
—
···
—
···
—
···
—
···
—
···
—
···
—
···